Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$40.09

-0.88 (-2.15%)

08:05
06/03/19
06/03
08:05
06/03/19
08:05

PTC Therapeutics names Emily Hill as CFO

PTC Therapeutics announced the promotion of Emily Hill to CFO. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor Relations. Prior to joining PTC Therapeutics, Emily was Director of Investor Relations of Warner Chilcott.

  • 03

    Jun

  • 04

    Jun

  • 12

    Jun

PTCT PTC Therapeutics
$40.09

-0.88 (-2.15%)

05/13/19
BOFA
05/13/19
UPGRADE
BOFA
Buy
PTC Therapeutics upgraded to Buy from Neutral at BofA/Merrill
05/13/19
BOFA
05/13/19
UPGRADE
Target $49
BOFA
Buy
PTC Therapeutics upgraded to Buy following data update at BofA/Merrill
As previous reported, BofA/Merrill analyst Tazeen Ahmad upgraded PTC Therapeutics to Buy from Neutral and raised its price target to $49 from $43 following the data update at the American Academy of Neurology conference for risdiplam in the treatment of spinal muscular atrophy. Ahmad now has a higher conviction risdiplam will reach the market and be successfully marketed by partner Roche. His un-risk adjusted peak sales estimate is $4.8B, much higher than PTC's $2B estimate, equating to $700M in royalty payments in peak sales years. Tazeen also updated his model to include $75M i pipeline value for the company's early stage gene splicing program and expects investor interest to start to shift to PTC's fully owned pipeline in the near future.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/28/19
CANT
05/28/19
NO CHANGE
Target $61
CANT
Overweight
PTC Therapeutics remains a top small-mid-cap franchise pick at Cantor Fitzgerald
After traveling with management, Cantor Fitzgerald analyst Alethia Young says PTC Therapeutics remains a top small-mid-cap franchise pick. The company has "many realizable shots on goal" that remain unappreciated at current share levels, Young tells investors in a research note. She thinks investors assign little credit to PTC's AADC deficiency opportunity in gene therapy. Young models peak sales of $400M and a 20% probability of success. The analyst reiterates an Overweight rating on PTC Therapeutics with a $61 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.